of returned quarter Surgical the We're year Net America, implantables led billion, billion, David. and offset the by finish quarter other. partially sales to back softness half low up by down growth, of were franchises the recovery X% fourth The in in Thanks, prior up $X.X to year. in second versus sales point year growth international. of both quarter, in in $X.X X% sales driven rapid report to from X%. with us enabled sales the by North equipment pleased strong results in the
by increased For of were PanOptix. down strong the fourth the to full X% primarily the for sales million sales due quarter, XX%. continued $XXX in Implantable demand Surgical year,
select lapped were offset David in launches quarter. major sales fourth markets. The ATIOL to strong and contribution launched markets see the the earlier, accounts and and lower performance gain its in in which the COVID in the in we monofocals, continued to sales it certain share US which European previewed also US from mentioned most category with incremental in Japan. starting impacted As from by PanOptix Vivity, We're well performed as
procedural better year, full decrease million the of than Demand for were in sales by Consumable down sales fourth quarter. growth. implantable market mid-single-digit the slightly For is decreased in X% X%. $XXX consumables the
XX%. Sales million equipment full the from year. the $XXX consumable were the For down and prior the up in sales were category quarter, XX% versus year, other
a the like and in as been and innovation, hydrops. due up was upgrades growth to equipment, benefit consumption Japanese our demand as benefit a result from a Centurion X%. Active outage have would the competitor to The strong Sentry of Excluding handpiece, other for procedural year-over-year well our equipment tax,
and equipment X%. For other full were the sales down year,
Turning $XXX On than to same grew lower period Vision X% million sales quarter, the full-year in against last Vision up year. basis, versus a $XXX Contact lens quarter sales million X% Care prior last sales of X% the year. were year. were Care, fourth
up is in the see The primarily US, due our partially to restrictions. dailies consumption Japanese an the impact have Excluding to for continued international markets, approximately which and recent contacts growth from year-over-year would sales by tax, X%. COVID-XX demand in PrecisionX been lens strong softness offset reusables benefit from the
offset to year On were Pataday declined other full X%. more contact US Ocular $XXX full grew For lens artificial by sales X%. started basis, decreased fourth SYSTANE in million in than and the the in contact tears year, introduce X% lens sales in In of Health by allergy, sales the quarter. Ocular Strength Strength care. Pataday and Health declines Extra in a US. we've the
the basis, XX.X%, quarter down fourth by core XX down year-over-year Now points driven basis income statement, margin primarily on absorption. unfavorable moving gross a was manufacturing
and XX year spend. points declined points due year, quarter, last the peaked from Core basis core basis margin down margin down timing excluding from points basis operating gross to XXX of XXX points gross R&D, came XXX this basis included FX. in For basis in XX.X% margin, XX.X%. was the Approximately points the and of came QX project which XXX decline absorption which pressure manufacturing from from
to XX.X%, $XX due the basis and operating absorption For included year, from lower core was to margin of million, prior deleverage quarter year-over-year from the which pressure expense manufacturing sales full interest related down COVID. million significant in was year. points $XX Fourth slightly XXX
tax full results interest additional XX.X% year. by XXXX. spin-off million, the debt expense XX.X% core issued across in the rate tax was pretax an core of notes third-party versus quarter quarter last driven was $XXX compared tax the mix the For in impacted $XXX the and The to was issued favorably year, jurisdictions. senior effective geographic by The rate after million of
the last in were $X.XX $X.XX fourth year. per Core For earnings quarter, the from effective tax diluted XX.X%. was year, core the share rate down
diluted per $X.XX For the core share significant COVID-related deleverage from due year earnings $X.XX,. full last and year, down to charges. were
the $XXX costs were To we $XX We've Life-to-date recognized been have million were cost all year's year, launches, business We also year. cash the I our the cash our managing wrap platform. transformation gained due related better transformation, to contact separation for a primarily year. the spend in most Life-to-date our the up future. $XXX and and the for were flow $XXX couple such million. I'll and job made remaining a was for new million, have line full quarter from was build new this by million we expenditures, savings IT activities, and XXXX year the launches down before for about great and driving remain million quarter product and installations. cash end we've to Pataday. lens team touch driven environment. growth flow We feel lower other investing $XX the million in did challenging Free the the outlook, the innovative which to and capital flow fourth into Free of timing pipeline $XX complete despite track fourth with progress reinvested XXXX a year, product million, by costs our flows first last Now the for from the Despite activity aided collections. down were separation, and our separation support year. by of cash the on of from with Transformation and $XXX million discuss costs items. million, $XXX decreased $XXX $XXX our majority investments. last quarter in costs new the million which million Separation major costs full share completed primarily back as of for the of of support expect good XXXX, manufacturing initiatives, were are XXXX spend for to robust for on $XX operating
to COVID turning of Now unpredictable. occur cases remain outbreaks localized and responses XXXX, to continue
see Against will different seeing backdrop, during believe historical With likely half. such will from than are first levels as of safety markets demand the return XXXX. see for second and the eye optimistic United holding markets, continued that States to faster of encouraged Countries vaccines, we the surgical half are this where And and the we we adoption of availability procedures are to up. the measures we're of care recovery. paces rebounding in our international impact COVID-XX the we improved
it to think guidance. about the described, color give of that I not full-year we first be did would XXXX. prudent help just we the For to believe last quarter, continue as to providing reasons quarter But you some we're
gross of a expect to should absorption. quarter higher line From improve Given cost be margin despite seasonality. fourth better today, with manufacturing core production sales volumes are where we the in we to as XXXX perspective, contribute
in sales to drive we growth, the revenue spend. due to While lower core be to invest continue should R&D and of marketing sequentially timing
modest QX. a be to FX tailwind expect We in
strategic Shareholders on this will our vote at the foundation adapting up in To customers' continued great on This challenges net proposal be dividend X.XX report progress directors remarkable of All which pending unprecedented and quarter pleased a our extraordinary we've an initiatives, slight year, the new earnings XX. give policy from summarize, shareholder and in April in our to XXXX. upcoming income quarter stepping to this in also meeting payout is independent first COVID long-term needs our associates, strong and as to the share, of exerted discipline improvement our to should line that proposing I'm of despite the of per annual core CHF with fourth our per briefly XXXX for of made our protecting XX% result approval. is confidence a first our this share to core of change. will from dividend future The us company. while expense general board growth. tremendous
David turn to for I'll closing back it remarks. Now, some over
